Open AccessThe role of GLP-1/GIP receptor agonists in Alzheimer’s disease
Author(s) -
Chun Jiang Yu,
Dongying Ma,
Ling Song,
Zhen Nan Zhai,
Ye Tao,
Ying Zhang,
Lei Cai,
YoungChang Hou,
HongYuan Chen,
Li Wang
Publication year - 2020
Publication title -
advances in clinical and experimental medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.486
H-Index - 27
eISSN - 2451-2680
pISSN - 1899-5276
DOI - 10.17219/acem/121007
Subject(s) - liraglutide , sh sy5y , okadaic acid , apoptosis , endocrinology , medicine , neuroprotection , chemistry , pharmacology , cell culture , biology , biochemistry , neuroblastoma , enzyme , phosphatase , diabetes mellitus , genetics , type 2 diabetes
New glucagon-like peptide-1 (GLP-1) analogues developed in recent years have a long half-life and offer further prospects for clinical application. At present, the neuroprotection of GLP-1 analogues in Alzheimer's disease (AD) has just begun to be explored.